Skip to main content
Top
Published in: Arthritis Research & Therapy 5/2013

Open Access 01-10-2013 | Research article

How do people with knee osteoarthritis use osteoarthritis pain medications and does this change over time? Data from the Osteoarthritis Initiative

Authors: Sarah R Kingsbury, Elizabeth MA Hensor, Ceara AE Walsh, Marc C Hochberg, Philip G Conaghan

Published in: Arthritis Research & Therapy | Issue 5/2013

Login to get access

Abstract

Introduction

The aim of this analysis was to describe comprehensively the cross-sectional and longitudinal patterns of analgesic and nutraceutical medication use for knee osteoarthritis (OA) in a contemporary US cohort and to investigate associated demographic and clinical factors.

Methods

Baseline, 12, 24 and 36 month data were obtained retrospectively from the National Institutes of Health Osteoarthritis Initiative. Participants had symptomatic radiographic knee OA. Multiple binary logistic regression models identified characteristics independently associated with the use of analgesics or nutraceuticals.

Results

We included 987 subjects (55.9% female, mean age 61.5 years, 71.0% white). At baseline, 68.2% reported frequent use of a conventional analgesic or nutraceutical for joint pain (for more than half of the previous month). Non-prescription non-steroidal anti-inflammatory drugs (NSAIDs) were the most frequently reported medications (26.8%), even in those more than 75-years old. Multiple conventional analgesics were used by 11.9%. Frequent analgesic use was more likely in women (odds ratio (OR) 1.8 (95% confidence interval (CI) 1.3 to 2.3)) and people with more pain (moderate 1.7 (1.2 to 2.4); severe 3.1 (2.1 to 4.7)); nutraceutical use was less likely in non-whites (0.4 (0.3 to 0.6)), those more than 74-years old (0.6 (0.3 to 0.9)) and those with comorbidities (0.6 (0.5 to 0.9)) and more likely in people with Kellgren-Lawrence (KL) grade 4 (2.2 (1.5 to 3.3)). Overall there was no change in the proportion of participants frequently using prescription or over the counter (OTC) analgesics at 36 months, although most people had changed medication type; of those using a traditional analgesic at baseline approximately one third were still using the same type at 36 months (ranging from 26.2% of baseline prescription NSAID users to 40.6% of baseline acetaminophen users). All participants reporting baseline analgesic use also reported 36 month analgesic use. Female participants (OR 95% CI 1.2 to 3.2, P = 0.009), those with high body mass index (1.2 to 4.8, P = 0.010) and those with moderate (1.6 to 2.6, P = 0.090) or severe (1.8 to 12.0, P = 0.002) baseline pain were more likely to use pain medication during the 36 month follow-up period; participants more than 75-years old were less likely (0.2 to 1.0, P = 0.053).

Conclusions

Most people with knee OA used pharmacological therapies frequently, and use appeared to be according to American College of Rheumatology recommendations. Change in medication type used was common. Persistent non-prescription NSAID use in older people is an area of concern.
Appendix
Available only for authorised users
Literature
1.
go back to reference Keenan AM, McKenna SP, Doward LC, Conaghan PG, Emery P, Tennant A: Development and validation of a needs-based quality of life instrument for osteoarthritis. Arthritis Rheum. 2008, 59: 841-848.CrossRefPubMed Keenan AM, McKenna SP, Doward LC, Conaghan PG, Emery P, Tennant A: Development and validation of a needs-based quality of life instrument for osteoarthritis. Arthritis Rheum. 2008, 59: 841-848.CrossRefPubMed
2.
go back to reference Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R: Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003, 290: 2443-2454.CrossRefPubMed Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R: Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003, 290: 2443-2454.CrossRefPubMed
3.
go back to reference Yelin E, Sonneborn D, Trupin L: The prevalence and impact of accommodations on the employment of persons 51-61 years of age with musculoskeletal conditions. Arthritis Care Res. 2000, 13: 168-176.CrossRefPubMed Yelin E, Sonneborn D, Trupin L: The prevalence and impact of accommodations on the employment of persons 51-61 years of age with musculoskeletal conditions. Arthritis Care Res. 2000, 13: 168-176.CrossRefPubMed
5.
go back to reference Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997, 349: 1498-1504.CrossRefPubMed Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997, 349: 1498-1504.CrossRefPubMed
6.
go back to reference Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008, 58: 26-35.PubMedCentralCrossRefPubMed Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008, 58: 26-35.PubMedCentralCrossRefPubMed
7.
go back to reference Leigh JP, Seavey W, Leistikow B: Estimating the costs of job related arthritis. J Rheumatol. 2001, 28: 1647-1654.PubMed Leigh JP, Seavey W, Leistikow B: Estimating the costs of job related arthritis. J Rheumatol. 2001, 28: 1647-1654.PubMed
8.
go back to reference Allen KD, Helmick CG, Schwartz TA, DeVellis RF, Renner JB, Jordan JM: Racial differences in self-reported pain and function among individuals with radiographic hip and knee osteoarthritis: the Johnston County Osteoarthritis Project. Osteoarthritis Cartilage. 2009, 17: 1132-1136.PubMedCentralCrossRefPubMed Allen KD, Helmick CG, Schwartz TA, DeVellis RF, Renner JB, Jordan JM: Racial differences in self-reported pain and function among individuals with radiographic hip and knee osteoarthritis: the Johnston County Osteoarthritis Project. Osteoarthritis Cartilage. 2009, 17: 1132-1136.PubMedCentralCrossRefPubMed
9.
go back to reference Allen KD, Oddone EZ, Coffman CJ, Keefe FJ, Lindquist JH, Bosworth HB: Racial differences in osteoarthritis pain and function: potential explanatory factors. Osteoarthritis Cartilage. 2010, 18: 160-167.CrossRefPubMed Allen KD, Oddone EZ, Coffman CJ, Keefe FJ, Lindquist JH, Bosworth HB: Racial differences in osteoarthritis pain and function: potential explanatory factors. Osteoarthritis Cartilage. 2010, 18: 160-167.CrossRefPubMed
10.
go back to reference Stubbs D, Krebs E, Bair M, Damush T, Wu J, Sutherland J, Kroenke K: Sex Differences in pain and pain-related disability among primary care patients with chronic musculoskeletal pain. Pain Med. 2010, 11: 232-239.CrossRefPubMed Stubbs D, Krebs E, Bair M, Damush T, Wu J, Sutherland J, Kroenke K: Sex Differences in pain and pain-related disability among primary care patients with chronic musculoskeletal pain. Pain Med. 2010, 11: 232-239.CrossRefPubMed
11.
go back to reference Dominick KL, Baker TA: Racial and ethnic differences in osteoarthritis: prevalence, outcomes, and medical care. Ethn Dis. 2004, 14: 558-566.PubMed Dominick KL, Baker TA: Racial and ethnic differences in osteoarthritis: prevalence, outcomes, and medical care. Ethn Dis. 2004, 14: 558-566.PubMed
12.
go back to reference Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P: OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010, 18: 476-499.CrossRefPubMed Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P: OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010, 18: 476-499.CrossRefPubMed
13.
go back to reference Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000, 43: 1905-1915. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000, 43: 1905-1915.
15.
go back to reference Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, Towheed T, Welch V, Wells G, Tugwell P: American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012, 64: 455-474.CrossRef Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, Towheed T, Welch V, Wells G, Tugwell P: American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012, 64: 455-474.CrossRef
16.
go back to reference Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Leeb B, Lequesne M, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Serni U, Swoboda B, Verbruggen G, Zimmerman-Gorska I, Dougados M: EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003, 62: 1145-1155.PubMedCentralCrossRefPubMed Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Leeb B, Lequesne M, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Serni U, Swoboda B, Verbruggen G, Zimmerman-Gorska I, Dougados M: EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003, 62: 1145-1155.PubMedCentralCrossRefPubMed
17.
go back to reference Kelly JP, Kaufman DW, Kelley K, Rosenberg L, Anderson TE, Mitchell AA: Recent trends in use of herbal and other natural products. Arch Intern Med. 2005, 165: 281-286.CrossRefPubMed Kelly JP, Kaufman DW, Kelley K, Rosenberg L, Anderson TE, Mitchell AA: Recent trends in use of herbal and other natural products. Arch Intern Med. 2005, 165: 281-286.CrossRefPubMed
18.
go back to reference Dominick KL, Ahern FM, Gold CH, Heller DA: Gender differences in NSAID use among older adults with osteoarthritis. Ann Pharmacother. 2003, 37: 1566-1571.CrossRefPubMed Dominick KL, Ahern FM, Gold CH, Heller DA: Gender differences in NSAID use among older adults with osteoarthritis. Ann Pharmacother. 2003, 37: 1566-1571.CrossRefPubMed
19.
go back to reference Dominick KL, Dudley TK, Grambow SC, Oddone EZ, Bosworth HB: Racial differences in health care utilization among patients with osteoarthritis. J Rheumatol. 2003, 30: 2201-2206.PubMed Dominick KL, Dudley TK, Grambow SC, Oddone EZ, Bosworth HB: Racial differences in health care utilization among patients with osteoarthritis. J Rheumatol. 2003, 30: 2201-2206.PubMed
20.
go back to reference Dominick KL, Bosworth HB, Jeffreys AS, Grambow SC, Oddone EZ, Horner RD: Racial/ethnic variations in non-steroidal anti-inflammatory drug (NSAID) use among patients with osteoarthritis. Pharmacoepidemiol Drug Saf. 2004, 13: 683-694.CrossRefPubMed Dominick KL, Bosworth HB, Jeffreys AS, Grambow SC, Oddone EZ, Horner RD: Racial/ethnic variations in non-steroidal anti-inflammatory drug (NSAID) use among patients with osteoarthritis. Pharmacoepidemiol Drug Saf. 2004, 13: 683-694.CrossRefPubMed
21.
go back to reference Dominick KL, Bosworth HB, Dudley TK, Waters SJ, Campbell LC, Keefe FJ: Patterns of opioid analgesic prescription among patients with osteoarthritis. J Pain Palliat Care Pharmacother. 2004, 18: 31-46.CrossRefPubMed Dominick KL, Bosworth HB, Dudley TK, Waters SJ, Campbell LC, Keefe FJ: Patterns of opioid analgesic prescription among patients with osteoarthritis. J Pain Palliat Care Pharmacother. 2004, 18: 31-46.CrossRefPubMed
22.
go back to reference Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA: Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002, 287: 337-344.CrossRefPubMed Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA: Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002, 287: 337-344.CrossRefPubMed
23.
go back to reference Masso Gonzalez EL, Patrignani P, Tacconelli S, Garcia Rodriguez LA: Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010, 62: 1592-1601.CrossRefPubMed Masso Gonzalez EL, Patrignani P, Tacconelli S, Garcia Rodriguez LA: Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010, 62: 1592-1601.CrossRefPubMed
24.
go back to reference McGettigan P, Henry D: Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006, 296: 1633-1644.CrossRefPubMed McGettigan P, Henry D: Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006, 296: 1633-1644.CrossRefPubMed
25.
go back to reference Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbol EL, Sorensen R, Folke F, Buch P, Gadsboll N, Rasmussen S, Poulsen HE, Kober L, Madsen M, Torp-Pedersen C: Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009, 169: 141-149.CrossRefPubMed Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbol EL, Sorensen R, Folke F, Buch P, Gadsboll N, Rasmussen S, Poulsen HE, Kober L, Madsen M, Torp-Pedersen C: Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009, 169: 141-149.CrossRefPubMed
26.
go back to reference Fosbol EL, Gislason GH, Jacobsen S, Folke F, Hansen ML, Schramm TK, Sorensen R, Rasmussen JN, Andersen SS, Abildstrom SZ, Traerup J, Poulsen HE, Rasmussen S, Kober L, Torp-Pedersen C: Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther. 2009, 85: 190-197.CrossRefPubMed Fosbol EL, Gislason GH, Jacobsen S, Folke F, Hansen ML, Schramm TK, Sorensen R, Rasmussen JN, Andersen SS, Abildstrom SZ, Traerup J, Poulsen HE, Rasmussen S, Kober L, Torp-Pedersen C: Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther. 2009, 85: 190-197.CrossRefPubMed
27.
go back to reference Lanas A, Tornero J, Zamorano JL: Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis. 2010, 69: 1453-1458.CrossRefPubMed Lanas A, Tornero J, Zamorano JL: Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis. 2010, 69: 1453-1458.CrossRefPubMed
29.
go back to reference Charlson M, Szatrowski TP, Peterson J, Gold J: Validation of a combined comorbidity index. J Clin Epidemiol. 1994, 47: 1245-1251.CrossRefPubMed Charlson M, Szatrowski TP, Peterson J, Gold J: Validation of a combined comorbidity index. J Clin Epidemiol. 1994, 47: 1245-1251.CrossRefPubMed
30.
go back to reference Paradowski PT, Englund M, Lohmander LS, Roos EM: The effect of patient characteristics on variability in pain and function over two years in early knee osteoarthritis. Health Qual Life Outcomes. 2005, 3: 59-PubMedCentralCrossRefPubMed Paradowski PT, Englund M, Lohmander LS, Roos EM: The effect of patient characteristics on variability in pain and function over two years in early knee osteoarthritis. Health Qual Life Outcomes. 2005, 3: 59-PubMedCentralCrossRefPubMed
31.
go back to reference Neogi T, Nevitt MC, Yang M, Curtis JR, Torner J, Felson DT: Consistency of knee pain: correlates and association with function. Osteoarthritis Cartilage. 2010, 18: 1250-1255.PubMedCentralCrossRefPubMed Neogi T, Nevitt MC, Yang M, Curtis JR, Torner J, Felson DT: Consistency of knee pain: correlates and association with function. Osteoarthritis Cartilage. 2010, 18: 1250-1255.PubMedCentralCrossRefPubMed
32.
go back to reference Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, Brown C, Cooke TD, Daniel W, Gray R: The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum. 1990, 33: 1601-1610.CrossRefPubMed Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, Brown C, Cooke TD, Daniel W, Gray R: The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum. 1990, 33: 1601-1610.CrossRefPubMed
33.
go back to reference Gore M, Sadosky A, Leslie D, Tai KS, Seleznick M: Patterns of therapy switching, augmentation, and discontinuation after initiation of treatment with select medications in patients with osteoarthritis. Clin Ther. 2011, 33: 1914-1931.CrossRefPubMed Gore M, Sadosky A, Leslie D, Tai KS, Seleznick M: Patterns of therapy switching, augmentation, and discontinuation after initiation of treatment with select medications in patients with osteoarthritis. Clin Ther. 2011, 33: 1914-1931.CrossRefPubMed
34.
go back to reference Scholes D, Stergachis A, Penna PM, Normand EH, Hansten PD: Nonsteroidal antiinflammatory drug discontinuation in patients with osteoarthritis. J Rheumatol. 1995, 22: 708-712.PubMed Scholes D, Stergachis A, Penna PM, Normand EH, Hansten PD: Nonsteroidal antiinflammatory drug discontinuation in patients with osteoarthritis. J Rheumatol. 1995, 22: 708-712.PubMed
35.
go back to reference Zhao SZ, Wentworth C, Burke TA, Makuch RW: Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiol Drug Saf. 2004, 13: 277-287.CrossRefPubMed Zhao SZ, Wentworth C, Burke TA, Makuch RW: Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiol Drug Saf. 2004, 13: 277-287.CrossRefPubMed
36.
go back to reference Berger A, Bozic K, Stacey B, Edelsberg J, Sadosky A, Oster G: Patterns of pharmacotherapy and health care utilization and costs prior to total hip or total knee replacement in patients with osteoarthritis. Arthritis Rheum. 2011, 63: 2268-2275.CrossRefPubMed Berger A, Bozic K, Stacey B, Edelsberg J, Sadosky A, Oster G: Patterns of pharmacotherapy and health care utilization and costs prior to total hip or total knee replacement in patients with osteoarthritis. Arthritis Rheum. 2011, 63: 2268-2275.CrossRefPubMed
37.
go back to reference Report of the American College of Rheumatology Pain Management Task Force. Arthritis Care Res. 2010, 62: 590-599. Report of the American College of Rheumatology Pain Management Task Force. Arthritis Care Res. 2010, 62: 590-599.
38.
go back to reference Sun SX, Lee KY, Bertram CT, Goldstein JL: Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. Curr Med Res Opin. 2007, 23: 1859-1866.CrossRefPubMed Sun SX, Lee KY, Bertram CT, Goldstein JL: Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. Curr Med Res Opin. 2007, 23: 1859-1866.CrossRefPubMed
39.
go back to reference Lanza FL, Chan FK, Quigley EM: Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009, 104: 728-738.CrossRefPubMed Lanza FL, Chan FK, Quigley EM: Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009, 104: 728-738.CrossRefPubMed
40.
go back to reference American Geriatric Society Clinical Practice Guideline: Pharmacological Management of Persistent Pain in Older Persons. J Am Ger Soc. 2009, 57: 1331-1346. American Geriatric Society Clinical Practice Guideline: Pharmacological Management of Persistent Pain in Older Persons. J Am Ger Soc. 2009, 57: 1331-1346.
Metadata
Title
How do people with knee osteoarthritis use osteoarthritis pain medications and does this change over time? Data from the Osteoarthritis Initiative
Authors
Sarah R Kingsbury
Elizabeth MA Hensor
Ceara AE Walsh
Marc C Hochberg
Philip G Conaghan
Publication date
01-10-2013
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 5/2013
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar4286

Other articles of this Issue 5/2013

Arthritis Research & Therapy 5/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.